The Mark Cuban Cost Plus Drug Company and OncoPower (owned by Witty Health) have announced a collaboration to offer prescription drugs at a decreased cost.
The partnership will build on OncoPower’s cancer care support with the launch of a Medication Savings Suite, which leverages Cost Plus Drugs competitive pricing on generic medication to seamlessly allow the cancer patients that use OncoPower to look up pricing and order less expensive medications.
This Medication Savings Suite integrates with OncoPower’s Pill Reminder tool, creating an end-to-end experience for the patient that improves treatment adherence, provides cost transparency, engages the patient at home, and is completely free, opening up affordable access to supportive care for every cancer patient.
The relationship with OncoPower creates an additional channel for Cost Plus Drugs to offer its low-cost generic medications directly to a community of cancer patients, a patient population that struggles with taking many different medicines.
OncoPower is also launching an enhanced version of its Pill Reminder tool. It will alert patients of cheaper medication alternatives when they use Pill Reminder, fusing treatment adherence and cost transparency at the point of care for the patient. The patients will also be taken directly to Cost Plus Drugs online pharmacy to have drugs delivered to their homes. Closing the loop on these challenges for patients is needed progress.
OncoPower was launched as a response to the increasing complexity found in cancer care and the challenges that patients face in understanding and identifying the right clinical trials for participation. It is both an app and website with a social media style format in which patients and providers support one another, patients have access to professionals such as Registered Dietitians and Behavioral Therapists, high-quality cancer education and meditation content, and engaging tools for treatment adherence and clinical trial mapping.
Both companies have focused on direct-to-consumer messaging and this collaboration grows out of mutual values of transparent information and supporting patients through their care journey.
Join the HealthXL Meeting on ‘Standards for Robust Evidence from Digital Health in Oncology’ on 21st February. Click here to Request to Join.
Click here to read the original news story.